BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CP-4126: Phase II amended

Clavis disclosed in its 4Q10 earnings that it and partner Clovis amended the ongoing, open-label, international Phase II LEAP trial of CP-4126 to increase enrollment to 360 patients from 250. The company said the amendment will increase the statistical power of the trial from 80% to 90%, as well as...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >